Check how courts have cited this case. Use our free citator for the most current treatment.
No. 10655866
United States Court of Appeals for the Ninth Circuit
United States v. Alvear
No. 10655866 · Decided August 18, 2025
No. 10655866·Ninth Circuit · 2025·
FlawFinder last updated this page Apr. 2, 2026
Case Details
Court
United States Court of Appeals for the Ninth Circuit
Decided
August 18, 2025
Citation
No. 10655866
Disposition
See opinion text.
Full Opinion
NOT FOR PUBLICATION FILED
UNITED STATES COURT OF APPEALS AUG 18 2025
MOLLY C. DWYER, CLERK
U.S. COURT OF APPEALS
FOR THE NINTH CIRCUIT
UNITED STATES OF AMERICA, No. 24-6242
D.C. No.
Plaintiff - Appellee, 2:20-cr-00229-CDS-MDC-1
v.
MEMORANDUM*
WILLIAM ALVEAR,
Defendant - Appellant.
Appeal from the United States District Court
for the District of Nevada
Cristina D. Silva, District Judge, Presiding
Argued and Submitted August 12, 2025
Pasadena, California
Before: NGUYEN, FORREST, and VANDYKE, Circuit Judges.
Appellant-Defendant William Alvear (“Alvear”) was caught on film during
three separate controlled buys staged by the Federal Bureau of Investigations
(“FBI”) distributing and prescribing controlled substances to two confidential
human sources. A jury convicted him for three counts of distribution of a
controlled substance (Schedule II) in violation of 21 U.S.C. §§ 841(a)(1) &
*
This disposition is not appropriate for publication and is not precedent
except as provided by Ninth Circuit Rule 36-3.
(b)(1)(C) and five counts of distribution of a controlled substance in violation of 21
U.S.C. §§ 841(a)(1) & (b)(1)(C) (Schedule IV). Alvear moved for acquittal and a
new trial on the grounds of insufficient evidence and entrapment, which the district
court denied. We have jurisdiction under 28 U.S.C. § 1291, and we affirm.
1. “We review the district court’s denial of a motion for acquittal in the
same manner as a challenge to the sufficiency of the evidence.” United States v.
Ladum, 141 F.3d 1328, 1337 (9th Cir. 1998). Sufficiency of the evidence is a
“two-step inquiry” asking “whether ‘after viewing the evidence in the light most
favorable to the prosecution, any rational trier of fact could have found the
essential elements of the crime beyond a reasonable doubt.’” United States v.
Nevils, 598 F.3d 1158, 1163–64 (9th Cir. 2010) (en banc) (quoting Jackson v.
Virginia, 443 U.S. 307, 319 (1979)).
Under 21 U.S.C. § 841(a)(1), it is a federal crime “[e]xcept as
authorized . . . for any person knowingly or intentionally . . . to manufacture,
distribute, or dispense” a controlled substance. A violation under § 841(a)(1)
requires the government to prove that that the doctor knew or intended that the
prescription was unauthorized. Ruan v. United States, 597 U.S. 450, 468 (2022).
The evidence presented to the jury is sufficient to establish both that the
prescriptions were unauthorized and that Alvear knew. Dr. Timonthy Munzing,
testifying as an expert on lawful medical and prescription practices, opined that
2 24-6242
Alvear’s meeting with the confidential sources fell “far below the floor” of the
standard of care doctors should provide their patients if they are seeking to
prescribe medication for legitimate purposes. He pointed out that Alvear failed to
conduct medical examinations or review the patient histories of either source, that
the reasons the sources provided for needing prescriptions were unreliable and did
not warrant pain medication, and that Alvear accepted “tips” and appeared to
negotiate for money in exchange for prescriptions. Leo Basch, a pharmacist and
expert in the distributing and dispensing of controlled substances, told the jury that
Alvear failed to perform the mandatory database check to ensure the sources were
not being overprescribed narcotics. Basch also pointed out that when Alvear
handed the sources alprazolam, otherwise known as Xanax, during his meetings
with them, the drugs were not formally dispensed and often the sources provided
no medical reason for wanting the drug. This is sufficient evidence for a jury to
conclude the medication distributions were unauthorized. See Ruan, 597 U.S. at
467.
Because Alvear failed to perform basic reviews of the sources’ medical
history or give them formal examinations, a jury could easily conclude that he was
aware there was no medical basis for providing the drugs. See United States v.
Beecroft, 608 F.2d 753, 757 (9th Cir. 1979) (“Intent need not be established by
direct evidence, but may be inferred from the defendant’s statements and
3 24-6242
conduct.”). The footage from the sting operation also showed Alvear repeatedly
telling the sources that they did not need medication, yet he still provided
prescriptions and loose pills. Alvear additionally acted to conceal his conduct—
indicating that he knew it was criminal—by instructing the sources to go to certain
pharmacies that were unlikely to raise a warning about the prescription. There is
more than sufficient evidence to support the guilty verdict.
2. The same standard for evaluating the sufficiency of the evidence
supports a jury’s conclusion that a defendant was not entrapped. United States v.
Poehlman, 217 F.3d 692, 698 (9th Cir. 2000). “To raise entrapment, [a] defendant
need only point to evidence from which a rational jury could find that he was
induced to commit the crime but was not otherwise predisposed to do so.” Id.
Sufficient evidence supports the jury’s rejection of Alvear’s defense on either lack
of inducement or predisposition. See United States v. McClelland, 72 F.3d 717,
722 (9th Cir. 1995).
“An inducement consists of an opportunity plus something else—typically,
excessive pressure by the government upon the defendant or the government’s
taking advantage of an alternative, non-criminal type of motive.” Poehlman, 217
F.3d at 701 (citation omitted). Alvear identifies no evidence that distinguishes the
FBI’s operation from a normal sting operation. Sorrells v. United States, 287 U.S.
435, 441 (1932).
4 24-6242
More importantly, the jury was presented with significant evidence of his
predisposition, which “is the defendant’s willingness to commit the
offense prior to being contacted by government agents, coupled with the
wherewithal to do so.” Poehlman, 217 F.3d at 698; see also McClelland, 72 F.3d
at 722. One of the confidential sources had been receiving unauthorized narcotics
from Alvear since 2016, and the FBI began its operation only after it had learned
that Alvear was illegally distributing controlled substances. Alvear also provided
the drugs to the sources for money, and text messages shown to the jury revealed
that other individuals had paid him for unauthorized medications, too. The video
footage showed Alvear presented minimal to no reluctance when the sources
requested medications. Alvear also instructed the sources and the other customers
which pharmacies to use to avoid detection, demonstrating his experience and
willingness to help them fill their illicit prescriptions.
3. This court “review[s] a district court’s denial of a motion for a new trial
for abuse of discretion.” United States v. King, 660 F.3d 1071, 1076 (9th Cir.
2011) (citing United States v. Mack, 362 F.3d 597, 600 (9th Cir. 2004), and United
States v. Allen, 341 F.3d 870, 891 (9th Cir. 2003)). A motion for a new trial is to
be granted “only in exceptional cases in which the evidence preponderates heavily
against the verdict.” United States v. Pimental, 654 F.2d 538, 545 (9th Cir. 1981)
(citation omitted); see also Fed. R. Crim. P. 33(a). Alvear brings the same
5 24-6242
arguments he makes against the sufficiency of the evidence in support of his
request for a new trial, and they fail for the same reasons.
AFFIRMED.
6 24-6242
Plain English Summary
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS AUG 18 2025 MOLLY C.
Key Points
01NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS AUG 18 2025 MOLLY C.
02COURT OF APPEALS FOR THE NINTH CIRCUIT UNITED STATES OF AMERICA, No.
03Silva, District Judge, Presiding Argued and Submitted August 12, 2025 Pasadena, California Before: NGUYEN, FORREST, and VANDYKE, Circuit Judges.
04Appellant-Defendant William Alvear (“Alvear”) was caught on film during three separate controlled buys staged by the Federal Bureau of Investigations (“FBI”) distributing and prescribing controlled substances to two confidential human sourc
Frequently Asked Questions
NOT FOR PUBLICATION FILED UNITED STATES COURT OF APPEALS AUG 18 2025 MOLLY C.
FlawCheck shows no negative treatment for United States v. Alvear in the current circuit citation data.
This case was decided on August 18, 2025.
Use the citation No. 10655866 and verify it against the official reporter before filing.